Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
4-aminobutyrate transaminase (GABA-T), also known as GABA transaminase, is a mitochondrial enzyme (EC 2.6.1.19) that plays a critical role in the catabolism of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system. As a key component of the GABA shunt pathway, GABA-T converts GABA and α-ketoglutarate into succinic semialdehyde and glutamate. By regulating the breakdown of GABA, this enzyme controls its synaptic concentrations and modulates inhibitory tone in the brain. Pharmacological inhibition of GABA-T, for instance by vigabatrin, is a strategy used in antiepileptic therapies to increase GABA levels and enhance inhibitory neurotransmission.
Inhibition of GABA transaminase (GABA-T) leads to increased GABA levels in the central nervous system, thereby enhancing inhibitory neurotransmission. For example, vigabatrin irreversibly inhibits GABA-T.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 4-aminobutyrate transaminase (GABA-T).